Table 3.
Peptide mapping MS2 analysis of selected samples with false negative occurrences.
| Name | Chain | Number of methionine in chain | % Oxidized (intact level) | % Oxidized (peptide level) | Oxidation site | Predicted % SASA |
|---|---|---|---|---|---|---|
| lirilumab | Fd | 3 | 96 | 100 | M near end of H3 | 2 |
| trastuzumab | Fd | 2 | 56 | 79 | M near end of H3 | 2 |
| tocilizumab | Fd | 2 | 100 | 100 | M near end of H3 | 2 |
| imgatuzumab | Fd | 3 | 95 | 95 | M near end of H3 | 4 |
| gemtuzumab | LC | 1 | 74 | 85 | M at 48 in FR2 | 1 |
| ponezumab | LC | 1 | 90 | 86 | M at 4 in FR1 | 0 |
| motavizumab | LC | 2 | 58 | 68 | M at 4 in FR1 | 0 |